281 related articles for article (PubMed ID: 17295602)
1. Finasteride versus dutasteride: a real-world economic evaluation.
Fenter TC; Runken MC; Black L; Eaddy M
Am J Manag Care; 2007 Feb; 13 Suppl 1():S23-8. PubMed ID: 17295602
[TBL] [Abstract][Full Text] [Related]
2. Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men.
Naslund M; Eaddy MT; Kruep EJ; Hogue SL
Am J Manag Care; 2008 May; 14(5 Suppl 2):S167-71. PubMed ID: 18611091
[TBL] [Abstract][Full Text] [Related]
3. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
4. Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs.
Naslund M; Black L; Eaddy M; Batiste LR
Am J Manag Care; 2007 Feb; 13 Suppl 1():S17-22. PubMed ID: 17295601
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
Fenter TC; Davis EA; Shah MB; Lin PJ
Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
[TBL] [Abstract][Full Text] [Related]
6. 5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives.
Naslund M; Regan TS; Ong C; Hogue SL
Am J Manag Care; 2008 May; 14(5 Suppl 2):S148-53. PubMed ID: 18611088
[TBL] [Abstract][Full Text] [Related]
7. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
Issa MM; Lin PJ; Eaddy MT; Shah MB; Davis EA
Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
[TBL] [Abstract][Full Text] [Related]
9. Medical therapy for benign prostatic hyperplasia--present and future impact.
Issa MM; Regan TS
Am J Manag Care; 2007 Feb; 13 Suppl 1():S4-9. PubMed ID: 17295599
[TBL] [Abstract][Full Text] [Related]
10. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
11. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
Botto H; Lan O; Poulain JE; Comenducci A
Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
Gittelman M; Ramsdell J; Young J; McNicholas T
J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS
BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695
[TBL] [Abstract][Full Text] [Related]
14. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
15. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
[TBL] [Abstract][Full Text] [Related]
16. Finasteride to evaluate the efficacy of dutasteride in the management of patients with lower urinary tract symptoms and enlarged prostate.
Ravish IR; Nerli RB; Amarkhed SS
Arch Androl; 2007; 53(1):17-20. PubMed ID: 17364459
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway.
Johansen TE; Istad JA
Scand J Urol Nephrol; 2007; 41(2):124-31. PubMed ID: 17454951
[TBL] [Abstract][Full Text] [Related]
18. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
19. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia.
Lowe FC; McDaniel RL; Chmiel JJ; Hillman AL
Urology; 1995 Oct; 46(4):477-83. PubMed ID: 7571214
[TBL] [Abstract][Full Text] [Related]
20. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
